Genetic Epidemiology of Type 2 Diabetes in Mexican Mestizos

Table 1

Analyzed genes in studies about type 2 diabetes conducted in Mexican mestizos.

Gene	Chrom	dbSNP loc	Change	Effect	;	OR (95% CI)		Reference
ABCA1	9q31	rs9282541	C/T	R/C	244; 202	2.50 (1.48–4.24)	0.001	[7]
		rs2000069	C/T	Intronic	244; 202	1.08 (0.82–1.42)	0.58	[7]
		rs2230806	G/A	R/K	244; 202	1.17 (0.89–1.55)	0.27	[7]
		rs2487037	C/T	Intronic	244; 202	1.06 (0.79–1.43)	0.71	[7]
		rs3818689	G/C	Intronic	244; 202	0.94 (0.52–1.68)	0.82	[7]
ADAMTS9	3p14	rs4607103	C/T	Intronic	1027; 990	1.05 (0.91–1.20)	0.521	[8]
ADRB1	10q25	rs1801253	C/G	R/G	501; 552	0.79 (0.61–1.02)	0.07	[9]
ADRB3	8p11	rs4994	C/T	W/R	519; 547	1.69 (1.37–2.09)	0.0001	[10]
		rs4994	C/T	W/R	501; 552	1.34 (1.10–1.64)	0.004	[9]
ARHGEF11	1q21	rs945508	G/A	R/H	868; 504	0.91 (0.76–1.09)	0.319	[8]
CAPN10	2q37	rs3792267	G/A	Intronic	132; 112	0.97 (0.66–1.42)	0.86	[11]
		rs3792267	G/A	Intronic	719; 746	1.11 (0.95–1.29)	0.20	[12]
		rs3792267	G/A	Intronic	211; 152	0.91 (0.66–1.26)	0.56	[13]
		rs3842570	2R/3R	Intronic	132; 112	0.97 (0.68–1.40)	0.89	[11]
		rs3842570	2R/3R	Intronic	43; 64	1.81 (1.03–3.18)	0.038	[14]
		rs3842570	2R/3R	Intronic	211; 152	0.75 (0.55–1.02)	0.06	[13]
		rs5030952	C/T	Intronic	132; 113	0.85 (0.56–1.29)	0.45	[11]
		rs5030952	C/T	Intronic	211; 152	1.35 (0.89–2.06)	0.16	[13]
		rs2975760	T/C	Intronic	134; 113	2.72 (1.16–6.35)	0.017	[11]
CAPN10	2q37	rs7607759	A/G	T/A	127; 110	2.27 (0.98–5.25)	0.051	[11]
CDC123/CAMK1D	10p13	rs12779790	A/G	Intergenic	1027; 990	1.24 (1.05–1.47)	0.013	[8]
CDKAL1	6p22	rs10946398	A/C	Intronic	519; 547	1.09 (0.91–1.32)	0.337	[10]
		rs9465871	C/T	Intronic	519; 547	1.04 (0.85–1.26)	0.718	[10]
		rs7754840	C/G	Intronic	519; 547	1.08 (0.89–1.29)	0.438	[10]
		rs7754840	C/G	Intronic	1027; 990	1.13 (0.98–1.30)	0.081	[8]
CDKN2A/2B	9p21	rs10811661	C/T	Upstream	1027; 990	1.42 (1.15–1.75)	0.001	[8]
CRP	1q23	rs1130864	C/T	3′-UTR	166; 130	1.59 (1.15–2.22)	0.005	[15]
		rs1205	G/A	3′-UTR	166; 130	0.82 (0.59–1.14)	0.24	[15]
		rs2794521	A/G	5′-flanking	166; 130	1.97 (1.15–3.38)	0.012	[15]
		rs3093062	G/A	Promoter	166; 130	3.49 (0.98–12.4)	0.039	[15]
ELMO1	7p14	rs1345365	A/G	Intronic	148; 269	1.37 (1.02–1.84)	0.035	[16]
ENPP1	6q23	rs1044498	A/C	K/Q	519; 547	0.94 (0.76–1.16)	0.577	[10]
EXT2	11p11	rs3740878	A/G	Intronic	455; 234	0.83 (0.65–1.05)	0.054	[17]
FTO	16q12	rs8050136	A/C	Intronic	868; 504	0.90 (0.74–1.09)	0.278	[8]
		rs9939609	A/T	Intronic	519; 547	1.25 (1.02–1.54)	0.027	[10]
HHEX	10q23	rs5015480	C/T	Upstream	519; 547	0.96 (0.80–1.14)	0.631	[10]
		rs1111875	C/T	3′-flanking	1027; 990	1.01 (0.89–1.16)	0.859	[8]
		rs1111875	C/T	3′-flanking	455; 234	1.12 (0.88–1.44)	0.27	[17]
HHEX	10q23	rs7923837	A/G	3′-flanking	868; 504	1.21 (1.02–1.44)	0.025	[8]
HMOX1	22q12	rs2071749	A/G	Promoter	614; 956	0.98 (0.84–1.14)	0.76	[18]
IGF2BP2	3q27	rs4402960	G/T	Intronic	868; 504	1.24 (1.01–1.53)	0.042	[8]
IRS1	2q36	rs1801278	G/A	G/R	719; 746	2.04 (1.41–2.96)	<0.001	[12]
		rs1801278	G/A	G/R	444; 444	3.22 (1.99–5.20)	0.001	[19]
		rs1801276	C/G	P/A	444; 444	0.98 (0.72–1.32)	0.83	[19]
		rs3731594	G/A	N/D	444; 444	0.83 (0.42–1.66)	0.47	[19]
		rs1801108	G/C	R/P	444; 444	1.07 (0.85–1.34)	0.40	[19]
JAZF1	7p15	rs864745	T/C	Intronic	868; 504	1.24 (1.04–1.47)	0.015	[8]
KCNJ11	11p15	rs5215	C/T	V/I	519; 547	1.03 (0.87–1.23)	0.729	[10]
		rs5210	A/G	3′-UTR	519; 547	1.03 (0.86–1.23)	0.764	[10]
		rs5219	C/T	E/K	1027; 990	1.10 (0.96–1.26)	0.154	[8]
KCNQ1	11p15	rs2237892	C/T	Intronic	868; 504	1.36 (1.13–1.64)	0.001	[8]
LEPR	1p31	rs1137100	A/G	K/R	519; 547	1.00 (0.84–1.21)	0.92	[10]
LOC387761	11p12	rs7480010	A/G	Intronic	455; 234	1.43 (1.05–1.94)	0.006	[17]
LTA	6p21	rs909253	A/G	Intronic	51; 48	1.98 (1.02–3.8)	0.041	[20]
MGEA5	10q24	MGEA5-14	A/T	Intronic	271; 244	1.60 (0.52–4.86)	0.404	[21]
NOTCH2	1p11	rs10923931	G/T	Intronic	1027; 990	1.04 (0.82–1.32)	0.731	[8]
NQO1	16q22	rs1800566	C/T	P/S	623; 993	0.98 (0.85–1.13)	0.76	[18]
NRF2	2q31	rs2364723	C/G	Intronic	625; 992	0.91 (0.79–1.05)	0.18	[18]
NRF2	2q31	rs6721961	C/A	Promoter	623; 989	0.89 (0.74–1.06)	0.18	[8]
NXPH1	7p22	rs757705	A/G	Intronic	868; 504	1.25 (1.05–1.48)	0.01	[8]
PPARG	3p25	rs1801282	C/G	P/A	719; 746	1.00 (0.81–1.24)	1.00	[12]
		rs1801282	C/G	P/A	1027; 990	1.10 (0.90–1.34)	0.342	[8]
		rs17793693	A/C	Intronic	519; 547	1.09 (0.91–1.31)	0.329	[10]
RALGPS2	1q25	rs2773080	A/G	Intronic	868; 504	0.90 (0.74–1.10)	0.315	[8]
RORA	15q22	rs7164773	C/T	Intronic	868; 504	1.08 (0.91–1.28)	0.357	[8]
SIRT1	10q21	rs3758391	C/T	Upstream	519; 547	1.29 (1.08–1.54)	0.004	[10]
SLC30A4	8q24	rs13266634	C/T	R/W	455; 234	1.01 (0.76–1.33)	0.92	[17]
		rs13266634	C/T	R/W	1027; 990	1.22 (1.05–1.41)	0.009	[8]
TCF7L2	10q25	rs7903146	C/T	Intronic	868; 504	1.04 (0.84–1.28)	0.735	[8]
		rs7903146	C/T	Intronic	200; 200	1.84 (1.05–3.20)	0.04	[12]
		rs7903146	C/T	Intronic	519; 547	1.48 (1.18–1.86)	0.0007	[10]
		rs7903146	C/T	Intronic	283; 271	1.25 (0.92–1.70)	0.16	[22]
		rs12255372	G/T	Intronic	200; 200	1.83 (1.21–2.76)	0.006	[12]
		rs12255372	G/T	Intronic	281; 268	1.78 (1.11–2.88)	0.017	[22]
		rs12255372	G/T	Intronic	519; 547	1.37 (1.06–1.76)	0.014	[10]
		DG10S478	STR CACA	Intronic	282; 274	1.62 (1.02–2.57)	0.041	[22]
TLR2	4q32	rs5743708	G/A	R/Q	321; 538	0.41 (0.04–3.7)	0.40	[23]
TLR4	9q33	rs4986790	A/G	D/G	321; 538	1.39 (0.42–4.56)	0.58	[23]
		rs4986791	C/T	T/I	321; 538	1.01 (0.32–3.18)	0.98	[23]
TNF-α	6p21	rs1800629	-308G/A	Upstream	51; 48	0.76 (0.31–1.85)	0.55	[20]
		rs1800629	-308G/A	Upstream	95; 87	4.66 (1.73–12.5)	0.001	[24]
		rs1800629	-308G/A	Upstream	259; 645	1.25 (0.83–1.87)	0.29	[25]
		rs361525	-238G/A	Upstream	259; 645	1.57 (1.07–2.29)	0.018	[25]
TSPAN8/LGR5	12q14–q21	rs7961581	C/T	Intergenic	868; 504	0.93 (0.73–1.17)	0.516	[8]
TXNIP	1q21	rs7211	C/T	3′ UTR	623; 969	0.97 (0.82–1.14)	0.67	[18]
UBQLNL	11p15	rs979752	C/T	Upstream	868; 504	1.04 (0.84–1.30)	0.70	[8]

Chrom: chromosome. Risk alleles are marked in bold. ; . Sample for cases and controls, respectively. Conventional OR (unadjusted) was assessed by us from allele or genotype frequencies reported. Largest was registered. Test without ancestry correction was considered. Combined datasets were registered. Risk was only observed in nonobese T2D patients (OR = 1.25; ). Only Genotypes of T2D patients and healthy controls were used in our analysis. Assessment derived from the sum of T2D patients (obese and nonobese). The authors reported a protector effect for the A allele (OR = 0.65; p < 0.001), but in our estimation we took as reference the A allele, since it is the most common. Significant analysis with ancestry correction was taken. Association was only found in early-onset T2D (OR = 1.39; ). Just the population of Guerrero was recorded due to possible overlapping of the patients from the Mexico City with [10]. The G allele was assessed as risk by the authors; but in our analysis we took the A allele, the same as that in previous studies.